All CGA/Switzer shareholders thank the CTN Directors. That pesky ASX intervention reduces Naos payment. Who's next ASIC?
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
